NCT02506959View on ClinicalTrials.gov

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 14, 2015

Primary Completion Date

June 3, 2024

Study Completion Date

June 3, 2024

Conditions

Plasma Cell LeukemiaPlasmacytomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma

Interventions

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous peripheral blood stem cell transplant

DRUG

Busulfan

Given IV

DRUG

Gemcitabine Hydrochloride

Given IV

DRUG

Melphalan

Given IV

DRUG

Panobinostat

Given PO

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo autologous peripheral blood stem cell transplant

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02506959 - Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter